ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,222.68
      0.16%
      US Tech 100
      17,650.00
      0.05%
      Dow Jones
      39,512.84
      0.32%
      Brent Oil
      82.585
      0.00%
      Bitcoin
      61,368.23
      0.94%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Vivoryon Therapeut (VVY)

      7. Vivoryon Therapeut (VVY) News

      VVY

      Vivoryon Therapeut (VVY)

      Vivoryon Therapeut
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:VVY
      DateTimeSourceHeadlineSymbolCompany
      05/08/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024EU:VVYVivoryon Therapeut
      04/24/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic UpdatesEU:VVYVivoryon Therapeut
      04/16/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024EU:VVYVivoryon Therapeut
      03/15/20242:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Changes to Board CompositionEU:VVYVivoryon Therapeut
      03/04/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
      01/08/20241:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024EU:VVYVivoryon Therapeut
      12/06/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
      11/28/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023EU:VVYVivoryon Therapeut
      11/07/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
      11/07/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
      10/26/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose DecisionEU:VVYVivoryon Therapeut
      10/23/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
      10/23/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
      10/17/20239:32AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
      10/17/20239:32AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
      10/05/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
      10/05/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
      09/15/20237:57AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the BoardEU:VVYVivoryon Therapeut
      09/07/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
      08/31/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023EU:VVYVivoryon Therapeut
      08/04/20235:35PMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023EU:VVYVivoryon Therapeut
      08/04/20235:30PMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive OfficerEU:VVYVivoryon Therapeut
      07/16/20233:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
      06/21/202312:02PMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General MeetingEU:VVYVivoryon Therapeut
      06/15/202311:49AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces CEO Transition PlanEU:VVYVivoryon Therapeut
      06/01/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Participate in Upcoming ConferencesEU:VVYVivoryon Therapeut
      05/26/20231:39AMGlobeNewswire Inc.Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 MillionEU:VVYVivoryon Therapeut
      05/25/202311:50AMGlobeNewswire Inc.Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild OfferingEU:VVYVivoryon Therapeut
      05/16/20231:00AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
      05/09/20231:02AMGlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023EU:VVYVivoryon Therapeut
       Showing the most relevant articles for your search:EU:VVY